Just ahead of the Q4 and full-year reporting season, Scrip takes a look at the prospects for Europe’s biggest biopharma firms and what 2023 is likely to hold in store for them in terms of growth, regulatory and market milestones.
While Roche continues to be the big beast of the European sector in terms of market cap and revenues it saw its prospects hit in 2022 as revenues from COVID-19 therapies dried up and key late-stage trial readouts for TIGIT